Zlatkov V, Shopova E, Marinova B, Katsarova M
Akush Ginekol (Sofiia). 1996;35(4):49-50.
The aim of this study is the clinical testing of the vaginal wide-range, antimicrobial, quinolone--Chlorchinaldin/0,2/by POLFA, which has a strong antibacterial, antifungal, trichomonal and keratoplastic effect. The medicine was used on 43 patients with complaints of aggravated fluor. The clinical, colposcopic and microbiologic study showed: candidiasis--in 16 trichomoniasis--in 8, bacterial vaginalis--in 3 and anaerobic vaginitis--in 2 patients. The rest of the women (14) had various aerobic microbial findings. The treatment was daily using one vaginal tablet, every night for 10 days. A control examination was carried out one week after the any of therapy. The results showed a positive clinical effect, since in 67.4% there were negative microbiological findings. The lack of effect in cases with bacterial vaginosis and anaerobic vaginitis was painted out. These results give reason to believe that the wide antimicrobial range of Chlorchinaldin B will be complementary to the currently used drugs in the treatment of vaginal infections.
本研究旨在对由POLFA生产的具有广泛抗菌作用的喹诺酮类药物——氯喹那多/普罗雌烯(0.2)进行临床试验,该药物具有强大的抗菌、抗真菌、抗滴虫及角质形成作用。该药物用于43例主诉阴道炎加重的患者。临床、阴道镜及微生物学研究显示:念珠菌病16例,滴虫病8例,细菌性阴道病3例,厌氧性阴道炎2例。其余14名女性有各种需氧微生物感染。治疗方法为每天使用1片阴道片,每晚1次,共10天。在任何一种治疗结束1周后进行对照检查。结果显示临床效果良好,因为67.4%的患者微生物学检查结果为阴性。指出了细菌性阴道病和厌氧性阴道炎患者治疗无效的情况。这些结果使人有理由相信,氯喹那多/普罗雌烯广泛的抗菌谱将补充目前用于治疗阴道感染的药物。